Logo image of ISRL

ISRAEL ACQUISITIONS CORP-A (ISRL) Stock Fundamental Analysis

NASDAQ:ISRL - Nasdaq - KYG496671010 - Common Stock - Currency: USD

13.325  +0.9 (+7.28%)

After market: 13.6 +0.28 (+2.06%)

Fundamental Rating

1

Overall ISRL gets a fundamental rating of 1 out of 10. We evaluated ISRL against 0 industry peers in the Unkown industry. ISRL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ISRL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ISRL was profitable.
In the past year ISRL had a positive cash flow from operations.
ISRL Yearly Net Income VS EBIT VS OCF VS FCFISRL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 2M 4M 6M

1.2 Ratios

Industry RankSector Rank
ROA 24.37%
ROE 101.27%
ROIC N/A
ROA(3y)-1.16%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ISRL Yearly ROA, ROE, ROICISRL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

ISRL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ISRL Yearly Profit, Operating, Gross MarginsISRL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for ISRL has been reduced compared to 1 year ago.
The debt/assets ratio for ISRL is higher compared to a year ago.
ISRL Yearly Shares OutstandingISRL Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M 25M
ISRL Yearly Total Debt VS Total AssetsISRL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

ISRL has an Altman-Z score of 5.62. This indicates that ISRL is financially healthy and has little risk of bankruptcy at the moment.
The Debt to FCF ratio of ISRL is 0.54, which is an excellent value as it means it would take ISRL, only 0.54 years of fcf income to pay off all of its debts.
ISRL has a Debt/Equity ratio of 0.56. This is a neutral value indicating ISRL is somewhat dependend on debt financing.
Although ISRL does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 0.54
Altman-Z 5.62
ROIC/WACCN/A
WACCN/A
ISRL Yearly LT Debt VS Equity VS FCFISRL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

ISRL has a Current Ratio of 1.32. This is a normal value and indicates that ISRL is financially healthy and should not expect problems in meeting its short term obligations.
A Quick Ratio of 1.32 indicates that ISRL should not have too much problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 1.32
Quick Ratio 1.32
ISRL Yearly Current Assets VS Current LiabilitesISRL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for ISRL have decreased strongly by -36.58% in the last year.
EPS 1Y (TTM)-36.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-79.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 74.03, which means the current valuation is very expensive for ISRL.
ISRL's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.31.
Industry RankSector Rank
PE 74.03
Fwd PE N/A
ISRL Price Earnings VS Forward Price EarningsISRL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF 35.78
EV/EBITDA N/A
ISRL Per share dataISRL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.1 0.2 0.3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ISRL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ISRAEL ACQUISITIONS CORP-A

NASDAQ:ISRL (6/13/2025, 8:11:42 PM)

After market: 13.6 +0.28 (+2.06%)

13.325

+0.9 (+7.28%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)05-14 2025-05-14
Earnings (Next)08-14 2025-08-14
Inst Owners49.81%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner Change0%
Market Cap84.61M
Analysts0
Price TargetN/A
Short Float %2.19%
Short Ratio1.28
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 74.03
Fwd PE N/A
P/S N/A
P/FCF 35.78
P/OCF 35.78
P/B 37.07
P/tB 37.07
EV/EBITDA N/A
EPS(TTM)0.18
EY1.35%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.37
FCFY2.8%
OCF(TTM)0.37
OCFY2.8%
SpS0
BVpS0.36
TBVpS0.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 24.37%
ROE 101.27%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-1.16%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 0.54
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 102.32%
Current Ratio 1.32
Quick Ratio 1.32
Altman-Z 5.62
F-Score8
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-36.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-79.25%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1022.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1022.03%
OCF growth 3YN/A
OCF growth 5YN/A